12:00 AM
 | 
Jun 03, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Reolysin: Preliminary Phase II data

Preliminary data from 14 patients with metastatic melanoma in the first stage of the 2-stage, single-arm, open-label, U.S. Phase II REO 020 trial showed that IV Reolysin plus paclitaxel and carboplatin led to 3 partial responses and 7 cases of stable disease for a DCR of 71.5%. Oncolytics said the first stage of the trial therefore met its primary endpoint of...

Read the full 283 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >